VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-29.36	-29.36	-59.25	-48.71	-42.32	-22.04
Depreciation & Amortization	0.57	0.57	0.53	0.71	0.48	0.1
Share-Based Compensation	2.18	2.18	3.34	3.48	2.31	3.82
Other Operating Activities	0.8	0.8	5.66	-1.69	3.08	1.09
Operating Cash Flow	-25.81	-25.81	-49.72	-45.26	-12.07	-15.76
Capital Expenditures	-0.06	-0.06	-0.21	-0.2	-0.28	0
Acquisitions	0	0	-0.53	0	0	0
Investing Cash Flow	-0.06	-0.06	-0.74	-0.2	-0.28	0
Share Issuance / Repurchase	129.39	129.39	-0.01	10.49	114.48	4.31
Debt Issued / Paid	-0.99	-0.99	-1.03	-0	-0.38	-0.3
Financing Cash Flow	128.4	128.4	-1.04	10.48	114.1	4.01
Net Cash Flow	102.53	102.53	-51.5	-34.97	101.75	-11.75
Free Cash Flow	-25.87	-25.87	-49.93	-45.46	-12.35	-15.76
Free Cash Flow Margin	-2431.77%	-2431.77%	-	-4099.28%	-1133.45%	-
Free Cash Flow Per Share	-1.34	-1.34	-7.17	-6.89	-4.30	-9.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).